Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
CI Stock Summary
Top 10 Correlated ETFs
CI
In the News
Cigna (CI) Surpasses Market Returns: Some Facts Worth Knowing
Cigna (CI) reachead $363.34 at the closing of the latest trading day, reflecting a +1.57% change compared to its last close.
Why Cigna (CI) is a Top Value Stock for the Long-Term
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.
Brokers Suggest Investing in Cigna Group (CI): Read This Before Placing a Bet
The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price.
S&P 500 Achieves a New Milestone: Top 5 Non-Tech Picks
We have narrowed our search to five non-tech S&P 500 stocks that have provided double-digit returns year to date. These are: CI, RL, PH, ETN, EBAY.
Cigna (CI) Increases Yet Falls Behind Market: What Investors Need to Know
In the most recent trading session, Cigna (CI) closed at $352.63, indicating a +0.16% shift from the previous trading day.
CI or HUM: Which Is the Better Value Stock Right Now?
Investors looking for stocks in the Medical - HMOs sector might want to consider either Cigna (CI) or Humana (HUM). But which of these two stocks offers value investors a better bang for their buck right now?
Are These 3 Beaten-Down S&P 500 Members Worth a Look?
The market has enjoyed a fantastic run in 2024, building nicely on last year's gains. Up 8% YTD, the S&P 500's strong performance has been aided significantly by large-cap technology, with others also joining the party.
5 Low Price-to-Sales Stocks to Fetch Solid Portfolio Gains
The price-to-sales ratio is a convenient tool to gauge the value of stocks incurring losses or in an early development cycle. Stocks like PAGS, AMG, CI, BBSI and FIHL hold promise.
Cigna Group (CI) Soars to 52-Week High, Time to Cash Out?
Cigna (CI) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
CI Financial details
CI Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2023-12-31
Metric | History | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 408.98 | 439.96 | 515.66 | 534.5 | 664.15 | |
Net income per share | 13.58 | 23.17 | 15.89 | 19.84 | 17.57 | |
Operating cash flow per share | 25.23 | 28.36 | 21.28 | 25.61 | 40.2 | |
Free cash flow per share | 22.44 | 25.36 | 17.86 | 21.78 | 34.84 | |
Cash per share | 14.78 | 31.54 | 17.76 | 20.21 | 29.76 | |
Book value per share | 120.61 | 137.87 | 139.4 | 132.77 | 157.28 | |
Tangible book value per share | -95.19 | -80.66 | -96.84 | -98.69 | -97.9 | |
Share holders equity per share | 120.61 | 137.87 | 139.4 | 132.77 | 157.28 | |
Interest debt per share | 103.98 | 94.13 | 103.2 | 95.64 | 110.3 | |
Market cap | 76.87B | 75.98B | 77.61B | 111.98B | 88.01B | |
Enterprise value | 109.66B | 98.72B | 106.2B | 137.15B | 111.66B | |
P/E ratio | 15.06 | 8.98 | 14.45 | 16.7 | 17.04 | |
Price to sales ratio | 0.5 | 0.47 | 0.45 | 0.62 | 0.45 | |
POCF ratio | 8.1 | 7.34 | 10.79 | 12.94 | 7.45 | |
PFCF ratio | 9.11 | 8.21 | 12.86 | 15.21 | 8.59 | |
P/B Ratio | 1.7 | 1.51 | 1.65 | 2.5 | 1.9 | |
PTB ratio | 1.7 | 1.51 | 1.65 | 2.5 | 1.9 | |
EV to sales | 0.71 | 0.61 | 0.61 | 0.76 | 0.57 | |
Enterprise value over EBITDA | -1.18 | 8.57 | 9.42 | 11.02 | 21.62 | |
EV to operating cash flow | 11.56 | 9.54 | 14.77 | 15.84 | 9.45 | |
EV to free cash flow | 13 | 10.67 | 17.59 | 18.63 | 10.9 | |
Earnings yield | 0.07 | 0.11 | 0.07 | 0.06 | 0.06 | |
Free cash flow yield | 0.11 | 0.12 | 0.08 | 0.07 | 0.12 | |
Debt to equity | 0.83 | 0.65 | 0.71 | 0.69 | 0.67 | |
Debt to assets | 0.24 | 0.21 | 0.22 | 0.22 | 0.21 | |
Net debt to EBITDA | -0.35 | 1.97 | 2.54 | 2.02 | 4.58 | |
Current ratio | 1.01 | 1.3 | 2.84 | 2.67 | 0.77 | |
Interest coverage | -57.4 | 6.06 | 6.91 | 7.74 | 3.57 | |
Income quality | 1.85 | 1.22 | 1.33 | 1.28 | 2.29 | |
Dividend Yield | 0.01 | 0.06 | 0.02 | 0.01 | 0.02 | |
Payout ratio | 0.13 | 0.58 | 0.25 | 0.21 | 0.28 | |
Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
Research and developement to revenue | 0 | 0 | 0 | 0 | 0 | |
Intangibles to total assets | 0.52 | 0.51 | 0.52 | 0.54 | 0.51 | |
Capex to operating cash flow | -0.11 | -0.11 | -0.16 | -0.15 | -0.13 | |
Capex to revenue | -0.01 | -0.01 | -0.01 | -0.01 | -0.01 | |
Capex to depreciation | -0.29 | -0.39 | -0.39 | -0.44 | -0.52 | |
Stock based compensation to revenue | 0 | -0.03 | 0 | 0 | 0.05 | |
Graham number | 191.95 | 268.12 | 223.24 | 243.43 | 249.36 | |
ROIC | -0.9 | 0.08 | 0.08 | 0.1 | 0.06 | |
Return on tangible assets | 0.07 | 0.11 | 0.07 | 0.1 | 0.07 | |
Graham Net | -243.79 | -216.25 | -250.83 | -216.87 | -245.83 | |
Working capital | 314M | 6.71B | 16.9B | 18.02B | -11.37B | |
Tangible asset value | -35.79B | -29.44B | -32.73B | -33.35B | -28.77B | |
Net current asset value | -89.02B | -76.16B | -81.61B | -70.19B | -64.22B | |
Invested capital | 0.83 | 0.65 | 0.71 | 0.69 | 0.67 | |
Average receivables | 15.9B | 16.6B | 18.74B | 21.03B | 22.82B | |
Average payables | 15.31B | 17.18B | 12.74B | 7.22B | 8.16B | |
Average inventory | 2.74B | 2.91B | 3.44B | 4.25B | 5.21B | |
Days sales outstanding | 37.55 | 39.53 | 42.09 | 44.37 | 44.28 | |
Days payables outstanding | 184.09 | 210.06 | 72.38 | 88.12 | 86.03 | |
Days of inventory on hand | 31.52 | 35.32 | 40.48 | 54.14 | 56.78 | |
Receivables turnover | 9.72 | 9.23 | 8.67 | 8.23 | 8.24 | |
Payables turnover | 1.98 | 1.74 | 5.04 | 4.14 | 4.24 | |
Inventory turnover | 11.58 | 10.33 | 9.02 | 6.74 | 6.43 | |
ROE | 0.11 | 0.17 | 0.11 | 0.15 | 0.11 | |
Capex per share | -2.79 | -3 | -3.41 | -3.83 | -5.35 |
Quarterly Fundamentals Overview
Last date of statement is 2023-12-31 for Q4
Metric | History | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 153.15 | 157.11 | 165.06 | 166.8 | 174.63 | |
Net income per share | 3.91 | 4.28 | 4.96 | 0.14 | 3.52 | |
Operating cash flow per share | 7.03 | 17 | 8.46 | 9.61 | 5.02 | |
Free cash flow per share | 5.87 | 15.62 | 7.11 | 8.24 | 3.77 | |
Cash per share | 22.86 | 29.92 | 35.51 | 32.45 | 29.9 | |
Book value per share | 150.24 | 150.49 | 154.31 | 155.38 | 158.03 | |
Tangible book value per share | -111.67 | -112.67 | -108.65 | -106.67 | -98.36 | |
Share holders equity per share | 150.24 | 150.49 | 154.31 | 155.38 | 158.03 | |
Interest debt per share | 105.19 | 111.26 | 112.38 | 104.66 | 107.11 | |
Market cap | 98.96B | 75.56B | 82.64B | 84.12B | 87.59B | |
Enterprise value | 124.13B | 100.17B | 105.79B | 106.76B | 111.25B | |
P/E ratio | 21.16 | 14.91 | 14.15 | 512.93 | 21.28 | |
Price to sales ratio | 2.16 | 1.63 | 1.7 | 1.72 | 1.71 | |
POCF ratio | 47.15 | 15.03 | 33.16 | 29.77 | 59.71 | |
PFCF ratio | 56.42 | 16.36 | 39.45 | 34.72 | 79.48 | |
P/B Ratio | 2.21 | 1.7 | 1.82 | 1.84 | 1.89 | |
PTB ratio | 2.21 | 1.7 | 1.82 | 1.84 | 1.89 | |
EV to sales | 2.71 | 2.16 | 2.18 | 2.18 | 2.18 | |
Enterprise value over EBITDA | 52.64 | 49.71 | 47.63 | 47.66 | 108.11 | |
EV to operating cash flow | 59.14 | 19.92 | 42.45 | 37.78 | 75.83 | |
EV to free cash flow | 70.77 | 21.68 | 50.5 | 44.06 | 100.95 | |
Earnings yield | 0.01 | 0.02 | 0.02 | 0 | 0.01 | |
Free cash flow yield | 0.02 | 0.06 | 0.03 | 0.03 | 0.01 | |
Debt to equity | 0.69 | 0.73 | 0.72 | 0.68 | 0.67 | |
Debt to assets | 0.22 | 0.22 | 0.22 | 0.21 | 0.21 | |
Net debt to EBITDA | 10.67 | 12.21 | 10.42 | 10.11 | 22.99 | |
Current ratio | 2.67 | 0.72 | 0.73 | 0.73 | 0.77 | |
Interest coverage | 5.01 | 3.54 | 6.12 | -6.14 | 2.86 | |
Income quality | 1.75 | 3.85 | 1.65 | 1.95 | 1.43 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0.29 | 0.29 | 0.25 | 8.83 | 0.35 | |
Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
Research and developement to revenue | 0 | 0 | 0 | 0 | 0 | |
Intangibles to total assets | 0.54 | 0.53 | 0.52 | 0.52 | 0.51 | |
Capex to operating cash flow | -0.16 | -0.08 | -0.16 | -0.14 | -0.25 | |
Capex to revenue | -0.01 | -0.01 | -0.01 | -0.01 | -0.01 | |
Capex to depreciation | -0.47 | -0.54 | -0.53 | -0.53 | -0.48 | |
Stock based compensation to revenue | 0.01 | 0 | 0.03 | 0.03 | -0.06 | |
Graham number | 115.02 | 120.45 | 131.19 | 22.08 | 111.84 | |
ROIC | 0.02 | 0.01 | 0.02 | 0 | 0.08 | |
Return on tangible assets | 0.02 | 0.02 | 0.02 | 0 | 0.01 | |
Graham Net | -245.39 | -254.25 | -251.97 | -252.08 | -246.99 | |
Working capital | 18.02B | -12.7B | -12.63B | -12.54B | -11.37B | |
Tangible asset value | -33.35B | -33.32B | -32B | -31.37B | -28.77B | |
Net current asset value | -70.19B | -71.35B | -69.82B | -69.36B | -64.22B | |
Invested capital | 0.69 | 0.73 | 0.72 | 0.68 | 0.67 | |
Average receivables | 22.03B | 22.48B | 23.23B | 23.74B | 23.84B | |
Average payables | 15.66B | 7.57B | 7.72B | 7.87B | 8.11B | |
Average inventory | 4.4B | 4.49B | 4.36B | 4.47B | 5.03B | |
Days sales outstanding | 43.21 | 44.54 | 43.46 | 44.04 | 41.72 | |
Days payables outstanding | 21.73 | 73.23 | 80.42 | 77.36 | 82.95 | |
Days of inventory on hand | 13.35 | 41.9 | 44.97 | 44.52 | 54.75 | |
Receivables turnover | 2.08 | 2.02 | 2.07 | 2.04 | 2.16 | |
Payables turnover | 4.14 | 1.23 | 1.12 | 1.16 | 1.08 | |
Inventory turnover | 6.74 | 2.15 | 2 | 2.02 | 1.64 | |
ROE | 0.03 | 0.03 | 0.03 | 0 | 0.02 | |
Capex per share | -1.16 | -1.38 | -1.35 | -1.37 | -1.25 |
CI Frequently Asked Questions
What is Cigna Corporation stock symbol ?
Cigna Corporation is a US stock , located in Bloomfield of Ct and trading under the symbol CI
Is Cigna Corporation buy or a sell ?
32 stock analysts have 32 predictions with a medium analyst target price of $298.84. The lowest prediction is $225 and the highest is $372
What is CI stock prediction ?
With a median analyst target price of $366.5, 4 stock analysts have made 4 forecasts in last 90 days. $354 is the lowest and $372 is the greatest projection.
What is Cigna Corporation stock quote today ?
Cigna Corporation stock price is $363.19 today.
Is Cigna Corporation stock public?
Yes, Cigna Corporation is a publicly traded company.